Abstract
The early detection of changes to molecular pathways underlying Rheumatoid Arthritis (RA) is a key goal in Rheumatology. However, the standard disease scoring methods employed in the standard mouse model of RA, Collagen Induced Arthritis (CIA) cannot adequately quantify cellular or molecular processes. Here, we show that biofluorescence imaging can track in vivo processes contributing to disease and allow comparisons to be made of therapeutic drug efficacy earlier in disease progression.
Original language | English |
---|---|
Pages | S75-S75 |
Publication status | Published - 6 Oct 2011 |
Keywords
- bioimaging
- rheumatoid arthritis
- arthritis
- rheumatism